Adding DT2216 to chemo for relapsed solid tumors and FLC
Treatments studied
Part of Cancer clinical trials.
This trial is testing whether adding a new drug, DT2216, to standard chemotherapy can help treat solid tumors (not starting in the brain) or fibrolamellar carcinoma (FLC) that have come back or not responded to treatment. It's for children, teens, and young adults (ages 1 to 39).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 39 years old.
- You have a solid tumor (not starting in the brain) that has come back or not responded to treatment, OR you have fibrolamellar carcinoma (FLC) that has not responded to at least one prior treatment, and a special gene test confirms the DNAJB1:PRKACA change.
- You have finished prior cancer treatments and recovered from side effects (for example, at least 3 weeks since last chemo, 2 weeks since local radiation, 12 weeks since a stem cell transplant).
- Your blood counts (neutrophils and platelets) are at certain levels (usually without needing transfusions, unless the cancer has spread to bone marrow).
- Your kidneys and liver are working well (based on blood tests), and you have not had a specific type of targeted therapy called Bcl-xL inhibitors (like navitoclax or DT2216) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This trial tests a vaccine targeting a specific fusion protein found in fibrolamellar carcinoma, combined with two immunotherapy drugs and a glutamine blocker. It is for patients whose cancer has gotten worse despite previous treatment.
Hear when a new Recurrent Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.